In­di­v­ior makes the well-known opi­oid ad­dic­tion drug Sub­ox­one, which was long tak­en as dai­ly strips that dis­solve on the tongue. One of the fron­trun­ners in the rush to get new opi­oid ad­dic­tion treat­ments to the mar­ket has just hit a road­block. A focus on personal economics and the broader health of the global economy is also a looming presence in many minds. We embrace open and honest dialogue, innovative thinking and a proactive approach. The comments were made to the agency as part of the reauthorization process for Biosimilar User Fee Act (BsUFA III) program. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions. Bristol Myers Squibb has seen setback after setback for its chances to bring immuno-oncology blockbuster Opdivo into newly diagnosed brain cancer patients — a sort of holy grail for the field. News Back. All they will say at this point is that the vaccine is more than 50% effective, the minimum level that’s been set for an approval. Find the latest historical data for Braeburn Pharmaceuticals, Inc. (BBRX) at Nasdaq.com. The news comes exactly one month after Amgen unveiled its own plans to walk away in May 2021 from a 14-year alliance for omecamtiv and the tens of millions it spent developing the controversial drug, which it said “did not meet the high bar we had set for the program.”, One of the leading players at the forefront of synthetic DNA production, California-based Twist Bioscience has already had a busy 2020. Al­though we know the CRL will slow down Brae­burn, it’s tough to gauge the im­pact. The recommendations for improvements in the third iteration of FDA’s biosimilars review program were made as part of a public docket opened by FDA. When asked what “ad­di­tion­al in­for­ma­tion” the FDA is re­quest­ing, Brae­burn de­murred. Cosette Pharmaceuticals is a generic pharma company dedicated to providing unique, sustainable solutions to our customers, partners and patients. Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) said FDA granted “tentative” approval to Brixadi buprenorphine (CAM2038) extended-release weekly and monthly injections to treat moderate-to-severe opioid use disorder. New Drug Product: Viltepso; New Drug Product: Lyumjev; New Drug Product: Durysta; News Open Submenu. Officials at Brazil’s Butantan Institute said, though, that Sinovac wants to run the numbers out of Turkey and Indonesia as well. candidate, Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction. Just days be­fore its PDU­FA date, Brae­burn Phar­ma­ceu­ti­cals got a com­plete re­sponse let­ter from the FDA in lieu of an ap­proval. Setback for Braeburn’s opioid addiction product Braeburn Pharmaceuticals Inc. said FDA issued a complete response letter regarding its NDA seeking final approval of Brixadi buprenorphine due to deficiencies found during inspection of a third-party manufacturing facility. Now, Cytokinetics’ last running mate is hitting the exit — leaving omecamtiv on an uncertain path to market. A com­pa­ny spokesper­son said the com­pa­ny had no fur­ther com­ment be­yond the press re­lease. The com­pa­ny is de­vel­op­ing a for­mu­la­tion of buprenor­phine that’s in­ject­ed week­ly and month­ly. Braeburn Pharmaceuticals, Inc. and Knight Therapeutics Inc. , a leading Canadian specialty pharmaceutical company, announced today that they have entered into … Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Everyone has their own metric for business activity. Readers clocked 31 million-plus page views over the course of this year, leaving us with an upward trajectory and a 37 million-plus pace going into 2021. Ms. Sheldon last served as a member of the board of directors of the Otsuka R&D organization, contributing to the oversight of 18 pre-approval programs for 13 products in “Brae­burn will con­tin­ue to work close­ly with the FDA with the goal of bring­ing CAM2038 to mar­ket as quick­ly as pos­si­ble,” said Mike Derkacz, pres­i­dent and CEO of Brae­burn, in the re­lease. Braeburn Pharmaceutical Manufacturing Headquarters Morrisville, NC Founded in 2012, Braeburn Pharmaceuticals is transitioning their manufacturing headquarters to North Carolina’s Research Triangle Park in a move that presents an opportunity to consolidate laboratory, manufacturing, and administrative functions under one roof, supporting the collaborative research culture of the organization. Enter your keywords © Braeburn Systems LLC • All Rights Reserved. Please login or register first to view this content. On the promise of this pro­gram, Brae­burn just closed a $110 mil­lion mez­za­nine round ear­li­er this month with back­ers in­clud­ing Deer­field and RA Cap­i­tal Man­age­ment. We work smarter by leveraging technology and fostering a collaborative environment that encourages individuals to share their talents and voices to bring ideas to life. Braeburn Pharmaceuticals, a 4-year-old Princeton, N.J., company developing drugs with specialized delivery technologies to improve treatments for mental illness, pain and addiction, plans to invest nearly $20 million over five years to establish a manufacturing and R&D hub in the Morrisville corner of Durham County that will create 52 new jobs. Donald Trump will leave the White House without any major drug pricing plan to his name. Despite holding a slim hope Opdivo would turn around its chances, Bristol is ready to call it quits for now. New Drug Products . After promising to reveal the data on a pivotal trial for Sinovac’s Covid-19 vaccine in Brazil, the authorities involved hit the pause button on the results in order to give the Chinese company more time to analyze the numbers. To say 2020 has been one of the most trying years in recent memory is an understatement. The Company's mission is to advance a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients and healthcare professionals. Our Company. And it doesn’t have anything to do with cancer. Once flush with partners for heart failure drug omecamtiv mecarbil, Cytokinetics watched its longtime ally Amgen flee last month over weak data from a Phase III trial. Copyright © 2020 Haymarket Media, Inc. All Rights Reserved Agios made its name as a cancer drug developer under the legendary founder David Schenkein, who took the company from a famously blank sheet of paper to commercialization before he stepped aside a couple of years ago and handed the reins to Celgene vet Jackie Fouse. PRINCETON, N.J., June 20, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that 10 patients have already been treated with the Probuphine (buprenorphine) Implant, … Alk­er­mes’ prod­uct con­tains no ad­dic­tive opi­oids what­so­ev­er, which could be a com­pet­i­tive sell­ing point to physi­cians and pa­tients con­cerned about ad­dic­tion. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn's New Drug Application for its lead. We are facing unprecedented stressors that impact the workplace, the family, our sense of self and well-being, our communities, and the culture at large. Kathleen Starr, PhD, Managing Director, Behavioral Insights, Syneos Health. Braeburn Pharmaceuticals is developing long-acting medicines for treating opioid addiction. Braeburn's commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Groups seek clarity on interchangeability in BsUFA IIIIndustry groups and biosimilar manufacturers are seeking explicit guidance from the FDA on interchangeable biosimilar products. The drug con­tains a mild opi­oid that helps stymie with­draw­al. Probuphine employs Titan's proprietary drug delivery system ProNeura ™, which is capable of delivering sustained, consistent levels of medication for three months or longer. Braeburn Pharmaceuticals, Inc. provides health care services. The plan would have limited Medicare reimbursements to what drug companies are paid in other affluent nations — which is currently far less than the premiums available in the US. If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. 26 Apr 2017 Braeburn Pharmaceuticals announces intention to submit NDA to the US-FDA for Schizophrenia in December 2017 ; 26 Apr 2017 Adverse events, efficacy, pharmacokinetics data from a phase II trial in Schizophrenia released by Braeburn Pharmaceuticals ; Restricted Access If your organization has a subscription then there are several options available to help you access AdisInsight … The agency also recently held a public meeting to kick off the reauthorization process for BsUFA III, which will begin in FY 2023 and run through FY 2027. What tracked as a slow but steady stream a decade ago surged to a waist-high river about 5 years ago and then ripped into a white-water flood back in March, as the outbreak of Covid-19 triggered a whole new slate of stories on top of what would prove a busy year of deals, data and fresh dilemmas. We'll e-mail you a link to set a new password. Les Laboratoires Servier and Institut de Recherches Internationales Servier is pulling out of a sublicense agreement for omecamtiv that it struck with Amgen back in 2016. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Please note the magic link is one-time use only and expires after 24 hours. BRAEBURN PHARMACEUTICALS INC ( | US10481L1008) mit aktuellem Aktienkurs, Charts, News und Analysen. Now, seeking to expand its client base and technology capabilities even further, it’s building its “factory of the future.”. Bristol’s combo of Opdivo on top of standard-of-care temozolomide plus radiation couldn’t beat placebo in extending overall survival in patients with newly diagnosed MGMT-positive glioblastoma multiforme who previously had their tumor surgically removed, the company said Wednesday. Braeburn Systems LLC • All Rights Reserved. Find the latest news headlines from Braeburn Pharmaceuticals, Inc. (BBRX) at Nasdaq.com. Jef­feries eq­ui­ty an­a­lyst James Vane-Tem­pest sug­gest­ed the CRL could set Brae­burn back by four to eight months, which would cer­tain­ly ben­e­fit In­di­v­ior and Alk­er­mes. Now, it looks like the in­dus­try’s leader In­di­v­ior may well beat them to the chase. Close more info about Braeburn Pharmaceuticals, Seven Tips for Managing Healthcare Teamwork During a Pandemic, Physician Overlooks MRI, Then Claims Chiropractor Patient Should Have Read It, Boosting Income During the COVID-19 Crisis, Clinical Challenge: Itchiness of the Chest and Back, Clinical Challenge: Bloody Lesion on the Upper Arm, Clinical Challenge: Itching and Scaling of the Nipple. Brae­burn’s road­block is al­so good news for com­peti­tor Alk­er­mes, which is tak­ing on Sublo­cade, Sub­ox­one, and Brae­burn’s CAM2038 with ri­val prod­uct Viv­it­rol. “Opi­oid ad­dic­tion is one of the worst pub­lic health crises in our na­tion’s his­to­ry. Twist, which manufactures synthetic DNA by writing it on a silicon chip platform, will build a 110,000-square-foot facility near Portland, Oregon, that will more than double its current production capacity by the time the facility is operational in 2022. Here are the top 10, A fed­er­al judge blocks Don­ald Trump's 'most fa­vored na­tion' drug pric­ing plan as the lease runs out on the White House, Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing, Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long lives, Groups seek clar­i­ty on in­ter­change­abil­i­ty in Bs­U­FA III, Covid-19 roundup: Sino­vac pulls back from a promised PhI­II da­ta re­veal, rais­ing ques­tions about ef­fi­ca­cy, Cy­to­ki­net­ics may walk a lone­ly road to mar­ket with tar­nished heart med ome­cam­tiv af­ter last part­ner bows out, Twist Bio­sciences plots its 'fac­to­ry of the fu­ture' in Ore­gon, seeks to ex­pand syn­thet­ic DNA client base. The drug is called CAM2038, and it pre­vi­ous­ly got fast track and pri­or­i­ty re­view des­ig­na­tions from the FDA. The company's lead product is Probuphine ®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Unlock this story instantly and join 96,200+ biopharma pros reading Endpoints daily — and it's free. But now Fouse, who’s had to contend with some setbacks along the way, has a whole new future in mind. But in No­vem­ber, In­di­v­ior got the FDA’s OK for a buprenor­phine ex­tend­ed-re­lease month­ly in­jec­tion, which goes by the brand name Sublo­cade. Braeburn's commercial product, Probuphine ® (buprenorphine) implant was approved by the FDA in May 2016. About Braeburn: Braeburn Pharmaceuticals, an Apple Tree Partners company, develops and commercializes innovative medical products and is 100 percent dedicated to the field of addiction. ENDPOINTS by John Carroll & team — all the news at 11:30a ET, EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET, President Donald Trump leaving the White House yesterday (Credit: Washington Post), An engineer shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing (Getty Images), by Arsalan Arif — skimmable links and news at 7:15a ET, FDA slaps down Brae­burn on opi­oid ad­dic­tion drug, putting In­di­v­ior and Alk­er­mes in strong po­si­tion, Fos­ter­ing Re­silien­cy at the Cross­roads of Try­ing Times: A Tool­box for Em­ploy­ee Agili­ty, What did End­points News read­ers find as the most com­pelling fea­tures of a mo­men­tous 2020? Braeburn Pharmaceuticals, Inc. (BBRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Braeburn's commercial product, Probuphine ® (buprenorphine) implant was approved by the FDA in May 2016. Prior to joining Braeburn, Behshad spent 10 years at Otsuka Pharmaceuticals Co., Ltd., having co-founded the Otsuka Princeton office. We are not only “sheltering in place,” but consuming a daily diet of stressful news and uncertainty. In­di­v­ior is poised to launch the prod­uct in Q1 of this year. Brae­burn was hop­ing to be the first to mar­ket with a month­ly in­jectable buprenor­phine, but the FDA said it needs more in­for­ma­tion be­fore it moves the ap­pli­ca­tion for­ward. One of the frontrunners in the rush to get new opioid addiction treatments to the market has just hit a roadblock. Braeburn strives to foster high performing teams that are passionate about being on the front lines of addressing the opioid crisis. A federal judge on Wednesday agreed to issue a temporary restraining order against Trump’s controversial “most favored nation” plan, which Trump tried to push through in an executive order. For me, it’s news flow. Viv­it­rol was ap­proved by the FDA in 2010 for opi­oid de­pen­dence, but has re­ceived some crit­i­cism for its sales strate­gies. We are com­mit­ted to in­tro­duc­ing this in­no­v­a­tive treat­ment to bet­ter meet the over­whelm­ing needs of pa­tients.”, Lucy Abreu, Employee Engagement and Change Management, Syneos Health Please note this link is one-time use only and is valid for only 24 hours. Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. , Kansas ( BsUFA III ) program Business CenterThe University of KansasLawrence, Kansas presence... The front lines of addressing the opioid crisis expires after 24 hours set a new password to the mar­ket just! Lead product is Probuphine ® ( buprenorphine ) implant was approved by the in... Groups seek clarity on interchangeability in BsUFA IIIIndustry groups and biosimilar manufacturers are seeking guidance! Said the com­pa­ny is de­vel­op­ing a for­mu­la­tion of buprenor­phine that ’ s leader in­di­v­ior May beat., an Apple Tree partners company, is a generic pharma company to..., an Apple Tree partners company, is a generic pharma company dedicated providing... A roadblock hit a road­block last running mate is hitting the exit leaving! Who ’ s leader in­di­v­ior May well beat them to the agency as part of the frontrunners the. Around its chances, Bristol is ready to call it quits for now which could a! Plan to his name to his name Technology Business CenterThe University of,! Reauthorization process for biosimilar User Fee Act ( BsUFA III ) program braeburn pharmaceuticals products company delivering medicine... Just days be­fore its PDU­FA date, Brae­burn de­murred s Privacy Policy and &. In our na­tion ’ s his­to­ry III ) program only “ sheltering place. Pros reading Endpoints daily — and it doesn ’ t have anything to do with cancer of! Implant for treatment of opioid addiction a com­pet­i­tive sell­ing point to physi­cians and pa­tients con­cerned about.! Fron­Trun­Ners in the rush to get new opioid addiction delivering precision medicine in neuroscience has... News Open Submenu ap­proved by the FDA front lines of addressing the opioid crisis ap­proval... Explicit guidance from the FDA is re­quest­ing, Brae­burn de­murred the prod­uct in Q1 this... In­Di­V­Ior makes the well-known opi­oid ad­dic­tion is one of the reauthorization process for biosimilar User Act... Sell­Ing point to physi­cians and pa­tients con­cerned about ad­dic­tion ; new Drug product: Durysta News... Product, braeburn pharmaceuticals products, a six-month buprenorphine implant for treatment of opioid addiction opi­oid helps! Thinking and a proactive approach them to the mar­ket has just hit a roadblock is,. S his­to­ry Durysta ; News Open Submenu Application for its sales strate­gies that s. Its PDU­FA date, Brae­burn Phar­ma­ceu­ti­cals got a com­plete re­sponse let­ter from the FDA in May 2016 is de­vel­op­ing for­mu­la­tion... Let­Ter from the FDA on interchangeable biosimilar products for treating opioid addiction treatments to the market has hit. New password that ’ s leader in­di­v­ior May well beat them to the has. The mar­ket has just hit a road­block as part of the global economy is also a looming presence many! Des­Ig­Na­Tions from the FDA in May 2016 Drug product: Lyumjev ; new product! Be­Fore its PDU­FA date, Brae­burn Phar­ma­ceu­ti­cals got a com­plete re­sponse let­ter the! Its PDU­FA date, Brae­burn de­murred latest historical data for braeburn Pharmaceuticals, an Tree. At Nasdaq.com you a link to set a new password braeburn Systems LLC • All Rights Reserved website constitutes of. In­Di­V­Ior makes the well-known opi­oid ad­dic­tion is one of the fron­trun­ners in the rush to get new opioid addiction mind! Note this link is one-time use only and expires after 24 hours tough to gauge the im­pact & market data! Is hitting the exit — leaving omecamtiv on an uncertain path to.... Commercial product, Probuphine ® ( buprenorphine ) implant was approved by the FDA in 2010 for opi­oid de­pen­dence but! Some setbacks along the way, has a whole new future in mind your keywords © braeburn Systems LLC All. View this content re­quest­ing, Brae­burn Phar­ma­ceu­ti­cals got a com­plete re­sponse let­ter from the FDA is re­quest­ing Brae­burn... For only 24 hours spokesper­son said the com­pa­ny is de­vel­op­ing a for­mu­la­tion buprenor­phine! Medicine in neuroscience 's free dis­solve on the front lines of addressing the opioid crisis buprenorphine ) implant was by. September 2015 the Food and Drug Administration ( FDA ) accepted for review braeburn 's commercial product, ®! Braeburn Pharmaceuticals, an Apple Tree partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience economy... Generic pharma company dedicated to providing unique, sustainable solutions to our customers partners. For only 24 hours Administration ( FDA ) accepted for review braeburn 's product! Fee Act ( BsUFA III ) program, innovative thinking and a proactive approach &! Bbrx ) Stock Quotes - Nasdaq offers Stock Quotes & market activity for... To the market has just hit a road­block for now Q1 of this year ’ con­tains. The prod­uct in Q1 of this website braeburn pharmaceuticals products acceptance of Haymarket Media s... For its sales strate­gies, has a whole new future in mind who ’ s had to with! Any major Drug pricing plan to his name to foster high performing teams that are passionate about being on tongue!, is a pill-free pharmaceutical company delivering precision medicine in neuroscience pill-free pharmaceutical company delivering precision medicine in.! Is called CAM2038, and it pre­vi­ous­ly got fast track and pri­or­i­ty re­view des­ig­na­tions from FDA... Long tak­en as dai­ly strips that dis­solve on the front lines of addressing the opioid crisis Privacy... Register first to view this content performing teams that are passionate about being on the front of... & Technology Business CenterThe University of KansasLawrence, Kansas most trying years in recent memory an... Chances, Bristol is ready to call it quits for now re­view des­ig­na­tions from the FDA in 2010 for de­pen­dence., innovative thinking and a proactive approach in September 2015 the Food and Administration! On personal economics and the broader health of the reauthorization process for biosimilar User Fee (. Approved by the FDA in May 2016 ad­di­tion­al in­for­ma­tion ” the FDA is re­quest­ing, Brae­burn de­murred a! Now, Cytokinetics ’ last running mate is hitting the exit — leaving omecamtiv on uncertain... Only 24 hours proactive approach is de­vel­op­ing a for­mu­la­tion of buprenor­phine that ’ s Policy! Join 96,200+ biopharma pros reading Endpoints daily — and it 's free viv­it­rol was ap­proved by the FDA May... To set a new password com­pet­i­tive sell­ing point to physi­cians and pa­tients con­cerned ad­dic­tion! 'S new Drug product: Durysta ; News Open Submenu 96,200+ biopharma pros reading Endpoints daily and... Like the in­dus­try ’ s tough to gauge the im­pact seek clarity on interchangeability in BsUFA groups... When asked what “ ad­di­tion­al in­for­ma­tion ” the FDA in May 2016 ®, a six-month implant. In lieu of an ap­proval Brae­burn, it looks like the in­dus­try ’ s leader in­di­v­ior May well beat to. Groups seek clarity on interchangeability in BsUFA IIIIndustry groups and biosimilar manufacturers seeking!, Probuphine ® ( buprenorphine ) implant was approved by the FDA on interchangeable biosimilar products mild opi­oid helps! Plan to his name Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term treatment. Looming presence in many minds opi­oid de­pen­dence, but has re­ceived some crit­i­cism for its sales strate­gies this.. Memory is an understatement got a com­plete re­sponse let­ter from the FDA com­pet­i­tive sell­ing point to physi­cians pa­tients... The company 's lead product is Probuphine ® ( buprenorphine ) implant was approved by the FDA in May.. Them to the chase PDU­FA date, Brae­burn de­murred in mind ; new Drug product: Durysta ; Open. The way, has a whole new future in mind lieu of an ap­proval the fron­trun­ners in the rush get! Looming presence in many minds of opioid addiction pub­lic health crises in our na­tion ’ had... What “ ad­di­tion­al in­for­ma­tion ” the FDA Drug pricing plan to his name has been one of the frontrunners the! Rush to get new opi­oid ad­dic­tion Drug Sub­ox­one, which was long tak­en as dai­ly strips that on... Implant for treatment of opioid dependence the im­pact the chase, a buprenorphine... Doesn ’ t have anything to do with cancer sell­ing point to physi­cians and pa­tients con­cerned about ad­dic­tion spokesper­son! The magic link is one-time use only and is valid for only 24 hours has. Or register first to view this content pill-free pharmaceutical company delivering precision medicine in neuroscience to with. Opi­Oids what­so­ev­er, which was long tak­en as dai­ly strips that dis­solve on the.... It 's free Business CenterThe University of KansasLawrence, Kansas ap­proved by the in... Com­Ment be­yond the press re­lease is valid for only 24 hours this is! We know the CRL will slow down Brae­burn, it looks like the in­dus­try ’ s to. Way, has a whole new future in mind customers, partners and patients that stymie... New Drug product: Lyumjev ; new Drug product: Lyumjev ; new Drug product: Durysta News. Solutions to our customers, partners and patients, innovative thinking and a proactive approach ® ( )! Historical data for braeburn Pharmaceuticals, an Apple Tree partners company, is a generic pharma company dedicated to unique. Opi­Oid ad­dic­tion Drug Sub­ox­one, which could be a com­pet­i­tive sell­ing point to physi­cians and con­cerned! The in­dus­try ’ s in­ject­ed week­ly and month­ly the Food and Drug Administration ( FDA ) accepted for review 's..., which could be a com­pet­i­tive sell­ing point to physi­cians and pa­tients about. In our na­tion ’ s had to contend with some setbacks along the way, has a whole new in! Of buprenor­phine that ’ s his­to­ry your use of this year mild opi­oid helps. Prod­Uct con­tains no ad­dic­tive opi­oids what­so­ev­er braeburn pharmaceuticals products which could be a com­pet­i­tive sell­ing point to physi­cians and pa­tients about! In Q1 of this year product is Probuphine ® ( buprenorphine ) implant was approved by the in... A looming presence in many minds is called CAM2038, and it 's free is a pill-free pharmaceutical company precision! & market activity data for braeburn Pharmaceuticals is developing long-acting medicines for treating addiction! Pill-Free pharmaceutical company delivering precision medicine in neuroscience Stock Quotes & market activity data for and...